Screener
CG Oncology CGON Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $19.64M+34.3% | $33.7M-18.7% | $32.49M-87.4% | $45.15M+4.0% | $14.62M-41.9% | ||
| $1.01B+56.0% | $1.04B+61.1% | $709.67M+46.3% | $635.12M+27.7% | $646.43M+22.5% | ||
| $417K-25.8% | $1.28M+270% | $688K-11.9% | $515K+276% | $562K+209% | ||
| $1M— | $1.49M— | $1.57M— | $1.5M— | —— | ||
| $1.05B+56.0% | $1.1B+57.2% | $759.48M+0.7% | $695.79M+26.0% | $673.03M+19.4% | ||
| $14.71M+5,713% | $15.07M+5,610% | $15.6M+5,634% | $15.33M+24,232% | $253K+201% | ||
| $10.3M— | $10.3M— | $10.3M— | $10.3M— | —— | ||
| $545K— | $560K— | $575K— | $1.67M— | —— | ||
| $1.09B+54.8% | $1.14B+55.9% | $791.59M+4.9% | $729.91M+32.1% | $701.45M+24.3% | ||
| $12.73M+78.6% | $8.24M+22.4% | $5.71M-12.3% | $9.19M+126% | $7.13M+58.7% | ||
| $47.24M+55.5% | $35.22M+55.5% | $30.84M+44.3% | $30.53M+95.3% | $30.38M+156% | ||
| $3M— | $3M— | $3M— | $3M— | —— | ||
| $56.54M+81.9% | $43.48M+85.6% | $38.99M+82.0% | $42.27M+169% | $31.09M+160% | ||
| $9K+12.5% | $9K+12.5% | $8K0.0% | $8K+14.3% | $8K+14.3% | ||
| -$518.23M-76.4% | -$439.18M-74.0% | -$378.98M-73.9% | -$337.67M-81.4% | -$293.86M-77.3% | ||
| $1.03B+53.5% | $1.09B+54.9% | $752.6M+2.6% | $687.64M+28.1% | $670.36M+21.4% | ||
| $1.09B+54.8% | $1.14B+55.9% | $791.59M+4.9% | $729.91M+32.1% | $701.45M+24.3% |
FAQ
- What are CG Oncology's total assets?
- CG Oncology (CGON) holds $1.1B in total assets, up 54.8% year over year.
- How much debt does CG Oncology have?
- CG Oncology carries $8.8M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does CG Oncology have?
- CG Oncology holds $19.6M in cash and equivalents.
- Can CG Oncology cover its short-term obligations?
- Its current ratio is 22.22 — current assets exceed current liabilities.
- Where does CG Oncology's balance sheet data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
